RPCA
AQST icon

Running Point Capital Advisors’s Aquestive Therapeutics AQST Stock Holding History

Running Point Capital Advisors’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-10,000
Closed -$12K – 215
2022
Q3 		$12K Hold
10,000
– – 0.01% 193
2022
Q2 		$6K Hold
10,000
– – ﹤0.01% 210
2022
Q1 		$26K Buy
+10,000
New +$29.2K 0.02% 175

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VAFP
Vahanian & Associates Financial Planning Saratoga Springs, New York $25.3M AUM 39.42% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BCL
Bracebridge Capital LLC Boston, Massachusetts $3.73B AUM 33.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LI
Latash Investments Anchorage, Alaska $129M AUM 14.69% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Running Point Capital Advisors's AQST Position: Q4 2022 in Review

Running Point Capital Advisors sold out of Aquestive Therapeutics (AQST) in Q4 2022, closing a stake of 10,000 shares — an estimated $12K sold.

Running Point Capital Advisors first reported a position in AQST in Q1 2022 and held it in 3 quarters. The position peaked at $26K in Q1 2022. 37 funds tracked by Wall St. Rank hold AQST as of Q4 2022.

  • Running Point Capital Advisors reported no remaining Aquestive Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Running Point Capital Advisors sold 10,000 Aquestive Therapeutics shares in Q4 2022, an estimated $12K.
  • Running Point Capital Advisors first reported a position in Aquestive Therapeutics in Q1 2022 and held it in 3 quarters.
  • Running Point Capital Advisors's Aquestive Therapeutics position peaked at $26K in Q1 2022.
  • 37 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q4 2022.

Based on Running Point Capital Advisors's 13F filing for Q4 2022, filed 9 Feb 2023.